New hope for acoustic neuroma: direct brain infusion of avastin in early trial
NCT ID NCT01083966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether delivering the cancer drug bevacizumab (Avastin) directly into the brain's arteries can safely treat vestibular schwannoma (acoustic neuroma), a non-cancerous tumor that can cause hearing loss. The study enrolls up to 30 adults with growing tumors who are not good candidates for surgery or radiation. The main goal is to find the safest dose, while also checking if it improves hearing and shrinks the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (Avastin)
What this could lead to
If successful, this could offer a safer, less invasive way to deliver bevacizumab directly to the tumor, potentially preserving hearing and controlling tumor growth without surgery or radiation.
What could go wrong
This is a very early Phase I trial focused on safety and dosing, not yet proven to work. The study is currently suspended, and the approach carries risks from intraarterial infusion, such as stroke or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VESTIBULAR SCHWANNOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lenox Hill Brain Tumor Center
New York, New York, 10075, United States